D-0092-2024 Class II Ongoing
FDA drug recall D-0092-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 23, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Out of specification for dissolution. The recall status is ongoing. Affected quantity: 16,944 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 15, 2023
- Initiation Date
- Oct 23, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 16,944 bottles
Product description
Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.
Reason for recall
Failed Dissolution Specifications: Out of specification for dissolution.
Distribution pattern
Nationwide
Code information
Lot # 17230388, Exp. 01/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0092-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026